

BRCA 1 and 2 Genetic Testing (Sequence Analysis/Rearrangement)

Last Review Date: May 27, 2016

Number: MG.MM.LA.08fC

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

DEFINITIONS

Close relative	1 st , 2 nd , or 3 rd degree relative (a parent, full sibling, half sibling, child, grandparent, great-grandparent, grandchild, aunt, great aunt, uncle, great uncle, nephew, niece or first cousin).
Limited family history	Fewer than two first- or second-degree female relatives or female relatives surviving beyond 45 years in either lineage (maternal and paternal).

Guideline

Members are eligible for coverage of BRCA 1 and 2 genetic testing (sequencing analysis, founder mutations) when results will directly impact surveillance or treatment.

A. BRCA 1 and 2 sequencing analysis — 1, 2 or 3 must be met:

1. ≥ 3 close relatives on the same side of the family (including the member) have breast (either invasive or non-invasive) or ovarian cancer
2. < 3 close relatives on the same side of the family with breast or ovarian cancer, but any of the following are present:
 - a. Individual or close relative diagnosed with breast cancer at ≤ 45 years of age
 - b. Close relative identified with a detectable BRCA 1 or 2 mutation
 - c. Individual or a close relative diagnosed with breast cancer ≤ 50 years of age and any:
 - i. ≥ 1 close relative diagnosed with breast cancer at any age
 - ii. two primary breast cancers (including bilateral disease or two or more separate primary tumors in the same breast)
 - iii. there is an unknown or limited family history

- d. Individual diagnosed with breast cancer at any age and ≥ 1 close relative diagnosed with breast cancer ≤ 50 years of age
 - e. Individual or close relative diagnosed with 2 primary breast cancers (including bilateral disease or ≥ 2 more separate primary tumors in opposite breasts) and the first cancer was diagnosed at ≤ 50 years of age
 - f. Individual or close relative diagnosed with triple negative breast cancer at ≤ 60 years of age (Breast cancer that is negative for Estrogen receptor [ER], Progesterone receptor [PR] and HER2)
 - g. Individual was diagnosed with breast cancer ≤ 50 years of age and has a limited family history
 - h. Individual was diagnosed with breast cancer at any age and has ≥ 2 close blood relatives with pancreatic cancer or aggressive prostate cancer (Gleason score ≥ 7) at any age
 - i. Individual or close relative diagnosed with ovarian cancer at any age
 - j. Individual or close relative with breast cancer is male
 - k. Individual or close relative diagnosed with breast cancer at any age and at increased risk for specific mutation(s) secondary to ethnic background (e.g., Ashkenazi Jewish descent). (See [Limitations/Exclusions](#))
3. The member was diagnosed with pancreatic cancer **or** aggressive prostate cancer (Gleason score ≥ 7) at any age with ≥ 2 close relatives with breast and/or ovarian (including fallopian tube or primary peritoneal cancer) and/or pancreatic or aggressive prostate cancer (Gleason score ≥ 7) at any age.

B. Members are eligible for BRCA 1 and 2 rearrangement testing if the criteria for comprehensive sequence analysis are met and the analysis is negative.

Limitations/Exclusions

Authorization should initially be for the mutation(s) specific to the ethnic group in question (e.g., Multisite 3 BRCAAnalysis [or equivalent testing for founder mutations] for members of Ashkenazi descent). If multisite screening is negative, additional genetic testing (e.g., comprehensive sequence analysis) would be warranted if the member meets the remainder of the criteria above.

Requests that do not meet the testing criteria will be reviewed by a Medical Director.

Applicable Procedure Codes

81162	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (New Code 01-01-2016)
81211	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510 bp, exon 8-9 del 7.1kb)
81212	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185 delAG, 5385insC, 6174delT variants
81213	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants
81214	BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510 bp, exon 8-9 del 7.1kb)
81215	BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81216	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81217	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant

Applicable ICD-10 Diagnosis Codes

C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast

C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
D05.10	Intraductal carcinoma in situ of unspecified breast
D05.11	Intraductal carcinoma in situ of right breast
D05.12	Intraductal carcinoma in situ of left breast
D05.80	Other specified type of carcinoma in situ of unspecified breast
D05.81	Other specified type of carcinoma in situ of right breast

D05.82	Other specified type of carcinoma in situ of left breast
D05.90	Unspecified type of carcinoma in situ of unspecified breast
D05.91	Unspecified type of carcinoma in situ of right breast
D05.92	Unspecified type of carcinoma in situ of left breast
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z15.02	Genetic susceptibility to malignant neoplasm of ovary
Z80.3	Family history of malignant neoplasm of breast
Z80.41	Family history of malignant neoplasm of ovary
Z85.3	Personal history of malignant neoplasm of breast
Z85.43	Personal history of malignant neoplasm of ovary

References

1. U. S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. 2005 Sept. accessed at <http://ahrq.gov/clinic/uspstf/uspstfbrngen.htm>
2. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med. 2000 Feb;342(8):564-571.
3. Theriault RL, Carlson RW, Allred DC, et al. Breast Cancer. National Comprehensive Cancer Network clinical Practice Guidelines in Oncology. Version 2.2016. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 3, 2016.
4. Daly MB, Axilbund JE, Buys SS, et al. Genetic/Familial High Risk Assessment: Breast and Ovarian. National Comprehensive Cancer Network clinical practice guidelines in oncology. Version 2.2016. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed June 3, 2016 .
5. Breast Cancer Susceptibility 1 and 2 (BRCA 1/2) Gene Testing for Hereditary Breast and Ovarian Cancer (HBOC). Hayes GTE Report. Winifred S. Hayes, Inc. August 6, 2013.
6. Agata S, Viel A, Della Puppa L, et al. Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes Chromosomes Cancer. 2006 Sep;45(9):791-797.
7. Engert S, Wappenschmidt B, Betz B, et al. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Hum Mutat. 2008 Jul;29(7):948-958.
8. Gutierrez-Enriquez S, de la Hoya M, Martinez-Bouzas C, et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat. 2007 May;103(1):103-107.
9. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002;346 (21):1660-1662.
10. Kaback MM, Greendale K, Fonseca LM, et al., American College of Medical Genetics Foundation. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. Supported by the New York State Department of Health. 1999. accessed 10/24/06 at <http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm>
11. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.
12. Manguoglu E, Guran S, Yamac D, et al. Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay. Cancer Invest. 2011 Jan;29(1):73-77.
13. Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008 Sep;68(17):7006-7014.

14. Preisler-Adams S, Schonbuchner I, Fiebig B, et al. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin. *Cancer Genet Cytogenet*. 2006 Jul;168(1):44-49.
15. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRAC1 or BRCA2 mutations. *N Engl J Med*. 2002;346(21): 1616-1622.
16. Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA 1 and BRCA2 genes: review of the literature and report of a novel BRCA 1 mutation. *Breast Cancer Res Treat*. 2011 Jan;125(2):325-349.
17. Stadler ZK, Sloustrós E, Hansen SA, et al. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. *Breast Cancer Res Treat*. 2010 Sept;123(2):581-585.
18. Specialty-matched clinical peer review.
19. Woodward AM, Davis TA, Silva AG, et al. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. *J Med Genet*. 2005 May;42(5):e31.